The Impact of Brain-Derived Neurotrophic Factor Polymorphism and Stimulation Parameters on the Response to Repetitive Transcranial Magnetic Stimulation: A Systematic Review

Yi-Ling Kuo, PT, PhD<sup>1</sup>, Gracy Lin<sup>2</sup>, Stephen J. Glatt, PhD<sup>3,4,5</sup>

<sup>1</sup> Department of Physical Therapy Education, SUNY Upstate Medical University, Syracuse, NY

- <sup>2</sup> Norton College of Medicine, SUNY Upstate Medical University, Syracuse, NY
- $^3$  Department of Psychiatry and Behavioral Sciences, SUNY Upstate Medical University, Syracuse, NY
- <sup>4</sup> Department of Neuroscience and Physiology, SUNY Upstate Medical University, Syracuse, NY
- <sup>5</sup> Department of Public Health and Preventive Medicine, SUNY Upstate Medical University, Syracuse, NY

### **ABSTRACT**

**Introduction:** TMS has been a common technique used to stimulate neuromodulatory changes, which can have therapeutic effects. The underlying mechanism is still unknown, however it is thought to cause neuroplastic changes via LTD or LTP. However, the effects are highly variable, with demographics and baseline physiology thought to be playing a role.

**Objectives:** The purposes of this systematic review were to 1) examine how BDNF polymorphisms are related to the after-effects of rTMS in humans and 2) investigate the association between BDNF polymorphism and rTMS stimulation parameters as contributing factors to the response to rTMS.

**Materials and Methods:** Studies identified from PubMed, The Cochrane Library, and Embase were screened for eligibility. Data were extracted from the selected studies by one reviewer and verified by another reviewer. Risk of Bias was assessed using the Cochrane Collaboration's tool. Results were synthesized narratively.

**Results:** Of the 224 initial studies, 35 were included in this systematic review. 33 out of 35 studies had at least one domain of high or unclear risk of bias. 53% of the studies in healthy individuals showed differences in TMS-derived or behavioral measures between Val/Val homozygotes and Met allele carriers. The neuromodulatory effects were more reliable in Val/Val homozygotes than Met allele carriers. In stroke, neuromodulatory effects on corticospinal excitability and motor deficits were more evident in Val/Val homozygotes than Met allele carriers. Similarly, in depression, Val/Val homozygotes demonstrated more improvement in depression symptoms compared with Met allele carriers following rTMS. The role of BDNF polymorphism in other disorders remained unclear.

**Conclusion:** It remains inconclusive whether and how BDNF genotype impacts the effects of rTMS. Methodological heterogeneity in the stimulation parameters, such as dosage and excitatory or inhibitory protocols, interact with BDNF polymorphism and contribute to the response to rTMS.

**Keywords:** BDNF, Polymorphism, rTMS, Theta-burst stimulation, neuromodulation

#### **INTRODUCTION**

The rapid increase in the application of non-invasive brain stimulation (NIBS) has led to numerous breakthroughs in experimental and clinical neuroscience. Transcranial magnetic stimulation (TMS) has been the most used NIBS technique for studying cortical physiology and neuroplasticity. A high-current generator flows electrical current to the conducting coil and generates a magnetic field that induces an electric current to depolarize superficial axons and create action potentials in the cortex $1,2$ . The repetitive introduction of TMS pulses can alter brain function lasting for a period of time following the stimulation, typically tens of minutes, which is known as repetitive TMS (rTMS). The neuromodulatory effects of rTMS are dependent on the stimulation site, frequency, intensity of the magnetic pulses, and orientation of the coil. The consensus from the neuromodulation societies considers low-frequency stimulation of ≤1 Hz to be "inhibitory'', whereas high-frequency stimulation of ≥5 Hz to be ''excitatory" in modulating corticospinal excitability (CSE). The modified form of rTMS with a much higher stimulation frequency, called theta-burst stimulation (TBS), produces a longer-lasting neuromodulatory effect (up to 60 minutes) within a shorter stimulation time frame and at a lower intensity<sup>3</sup>. TBS is administered as a continuous (cTBS) train with inhibitory effects, or intermittent (iTBS) train with excitatory effects<sup>1</sup>. It is generally acknowledged that TBS modifies CSE with a robust change similar to the cellular processing of long-term depression (LTD) with an inhibitory effect and long-term potentiation (LTP) with an excitatory effect $1,4$ .

The mechanism underlying the neuroplastic changes associated with the transient or lasting rTMSmodulated CSE remains unclear<sup>4</sup>. rTMS-induced neuromodulatory effects are highly variable and it has been demonstrated that only approximately 50% of participants responded to TBS with anticipated experimental and therapeutic effects<sup>5</sup>. Inter- and intra-individual variability of rTMS is dependent on baseline demographics and physiological characteristics such as anthropometric measurements of the head and brain, pathological changes in the central and peripheral nervous systems, and past life experiences leading to neuroplastic changes<sup>6</sup>. rTMS is used as a treatment to intervene in the brain circuits and has been shown to demonstrate efficacy in psychiatric and neurologic disorders<sup>7</sup>. Even though rTMS has been FDA-approved for a few indications, lacking markers to predict treatment efficacy is a long-standing issue in the field of neuromodulation. It is important to identify potential responders to rTMS to enhance the cost-effectiveness of this technique given the highly variable nature of this technique<sup>4</sup>. Predictor studies will help to pinpoint individuals suitable for rTMS intervention. Demographics, neurophysiology, and genetic traits have been studied. Using demographic, neurobiological, and clinical factors as predictors of rTMS treatment response is critical to fill the knowledge gap in identifying candidates to receive rTMS treatment.

Brain-derived neurotrophic factor (*BDNF*) is one of the candidate genes that contribute to brain morphological and functional changes and plays a critical role in synaptic plasticity and neuroprotection, integrating the metabolic and behavioral responses to the environments<sup>8,9</sup>. The Val66Met (rs6265) variant is a functional nonsynonymous single nucleotide polymorphism (SNP) in the *BDNF* gene that encodes the *BDNF* protein on chromosome 11 (11p13). This SNP of *BDNF* is hypothesized to affect the heterogeneity of response to rTMS as the placement of Val or Met occurring at position 66 in the pro-region of the *BDNF* gene determines the distribution of *BDNF* in the brain<sup>10</sup>. As *BDNF* is essential in regulating synaptic plasticity and brain connectivity, the Val66Met polymorphism is associated with reduced activity-dependent *BDNF* release, which can lead to cognitive deficits and susceptibility to neurologic and psychiatric disorders<sup>11,12</sup>. Another frequently studied *BDNF* polymorphism is C270T (rs56164415), a variant of a C to T substitution in the  $5\Box$  untranslated region that impacts the transcription of the *BDNF* gene. *BDNF* C270T alters the efficacy of *BDNF* translation, which can lead to *BDNF* imbalance in the brain and has also been linked to neurologic and psychiatric disorders<sup>13</sup>.

There are increasing studies suggesting that *BDNF* polymorphism is a vital factor in identifying responders to rTMS. However, there is conflicting evidence on the impact of *BDNF* genotype on responsiveness to rTMS, which might be attributed to various physiological factors and stimulation parameters. Here, this systematic review aims to 1) examine how the rs6265 and rs56164415 *BDNF* polymorphisms are related to the after-effects of rTMS in humans and 2) investigate the association between *BDNF* polymorphism and rTMS stimulation parameters as contributing factors to the response to rTMS.

# **MATERIALS AND METHODS**

#### **2.1 Protocol**

The guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-analyses for Protocols 2015 (PRISMAm-P 2015) were used to conduct this systematic review. The protocol was registered in the PROSPERO.

#### **2.2 Eligibility Criteria**

Studies met the following eligibility criteria were included in this systematic review: (1) research in humans; (2) peer-reviewed studies published in English; (3) studies with accessible full-text; (4) original research; (5) participants classified and grouped according to *BDNF* genotype; (6) rTMS used as the non-invasive brain stimulation intervention; (7) outcomes measured pre and post rTMS

intervention to determine changes and treatment effects; (8) outcomes compared between groups with different *BDNF* genotypes or between groups receiving active and sham rTMS.

# **2.3 Search Strategy**

Electronic literature searches were performed using PubMed, The Cochrane Library, and Embase, up to November 2024. These databases were searched using keywords and medical subject headings (MeSH), including: 'rTMS' or 'repetitive transcranial magnetic stimulation' or 'TBS' or 'theta burst stimulation' and '*BDNF*' or 'brain-derived neurotrophic factor' and 'polymorphism' or 'genotype'. Titles and abstracts of the initial search results were screened for relevant studies meeting the inclusion criteria. Full-text versions of potentially eligible studies were then examined. A manual search of the reference lists of the eligible studies was also performed.

#### **2.4 Selection Process**

One reviewer (YLK) initially screened the titles and abstracts of the articles, and the eligibility of the screened studies was determined independently by all reviewers.

### **2.5 Outcome Measures**

The effects of rTMS or TBS on TMS-measured motor evoked potential (MEP) amplitudes were included as the neurophysiological outcomes. Outcomes other than TMS-derived measurements were included as behavioral outcomes or clinical outcomes.

#### **2.6 Data Extraction**

Demographic data extracted included the study population, sample size of each group, mean age, and sex. Brain stimulation-related data included the location of stimulation, side of stimulation (left or right hemisphere), stimulation protocol (stimulation frequency, session number, stimulation intensity, and number of stimuli), and sham stimulation. Methods of obtaining body fluid drawing and *BDNF* genotyping were extracted. Behavioral and clinical outcome measures obtained before and after rTMS or TBS were extracted. Data were independently extracted by one reviewer and verified by another reviewer (YLK and GL). The reviewers discussed any discrepancy in data to reach a consensus.

#### **2.7 Risk of Bias**

The Cochrane Collaboration's tool<sup>14</sup> was used to assess the risk of bias in each included study. The domains assessed the risk of selection bias, performance bias, detection bias, attrition bias, reporting bias, and other biases. The ratings were categorized as low, unclear, or high risk of bias. The risk of

bias in each included study was independently assessed by one reviewer and verified by another reviewer (GL and YLK).

### **RESULTS**

#### **3.1 Selection of Studies**

Electronic literature searches with keyword searches yielded a total of 224 studies. After removing the duplicates, 115 studies were included in the initial screening of titles and abstracts with the eligibility criteria. 74 studies were eliminated due to the following reasons: (1) studies were conference abstracts or proceedings (N = 16); (2) studies were reviews or commentaries (N = 18); (3) rTMS or TBS was not used as an intervention (N = 32); (4) articles were not written in English (N = 2); (5) records were protocol registrations ( $N = 6$ ); (6) studies were performed in animals ( $N = 5$ ); and (7) participants all had the same *BDNF* genotype and all received iTBS without a control condition (N = 1). As a result, 35 articles met the full eligibility criteria and were included in this systematic review. The selected studies were categorized according to population, including 17 studies in healthy individuals, nine in stroke, three in depression, one in spinocerebellar ataxia, one in Parkinson's Disease with levodopa-induced dyskinesias, one in Tourette syndrome, one in schizophrenia, one in autism spectrum disorder, and one with combined populations of older adults, Type-2 diabetes mellitus, and Alzheimer's disease. The PRISMA diagram (Figure 1) demonstrates the study inclusion process.

#### **3.2 Risk of Bias**

The risk of bias in the studies grouped by participant condition is presented in Figure 2. Risk of bias categories were "low risk of bias," "unclear risk of bias," or "high risk of bias." Most studies had a high or unclear risk of bias in three or more domains. Out of the total 35 studies, two had a high risk of bias for not using random sequence, five had a high risk of bias for not using allocation concealment, two had a high risk of bias for not blinding participants and researchers, one had a high risk of bias for not blinding outcomes assessment, 16 had a high risk of bias for incomplete outcome data, one had a high risk of selective reporting, and 17 had a high risk of other bias. Most studies did not include information regarding allocation concealment and blinding of outcome assessment. 33 out of 35 (94.3%) studies had at least one domain of unclear risk of bias.

#### **3.3** *BDNF* **Genotyping Methods**

Twelve studies obtained saliva samples to perform *BDNF* genotyping<sup>15-26</sup>, whereas other studies used venous blood samples. *BDNF* Val66Met polymorphisms were categorized as homozygous for valine in codon 66 (Val/Val), homozygous for methionine (Met), or Val/Met heterozygotes. Met/Met homozygotes

were less seen in the general population, and only four studies had sufficient sample size to group and compare participants across all polymorphisms (Val/Val versus Val/Met versus Met/Met)<sup>27-30</sup>. Individuals with variants of Val/Met and Met/Met were pooled as Met allele carriers in some studies to refer to individuals with the Met variant form of *BDNF*<sup>16,20,25,31–40</sup>. Only two studies genotyped the C270T polymorphisms: one in stroke<sup>34</sup> and one in schizophrenia<sup>41</sup>.

#### **3.4 Stimulation Parameters,** *BDNF* **Polymorphism, and Responses to rTMS**

Data extracted from the included studies are presented in Table 1. Low-frequency rTMS studies used 1 Hz, whereas high-frequency rTMS studies used 5, 10, and 20 Hz. TBS studies used 50 Hz as the stimulation frequency in both iTBS and cTBS. The stimulation sites included M1, frontal cortex, dorsal lateral prefrontal cortex (DLPFC), Broca's area, and cerebellum, with M1 being the most stimulated location. For single-session studies examining the immediate effects of rTMS and TBS, stimulation stimuli applied ranged from 250 to 1,500. For multi-session studies, rTMS and TBS were used as therapeutic interventions with neuromodulatory effects in some studies on stroke $30,34,35,37,42$  and depression<sup>39,43,44</sup>, as well as other disorders<sup>26,41,45</sup>. The treatment courses were five to 22 sessions over one to three weeks, with stimulation stimuli ranging from 300 to 1,800 per session.

#### *Healthy Individuals*

Most studies in healthy individuals targeted the left M1 at the representational area of the first dorsal interosseus (FDI) muscle, whereas some studies targeted the dominant M1 of the pharyngeal muscle<sup>17</sup>, dominant<sup>32</sup> or non-dominant<sup>27</sup> M1 of the FDI, right DLPFC<sup>15</sup>, and left frontal cortex<sup>16</sup>. Five studies administered rTMS (high and/or low frequency)<sup>15-17,27,31</sup>, and 14 studies administered TBS (iTBS and/or cTBS)<sup>18–22,28,29,31–33,46–49</sup>. Sub-threshold<sup>16,17,27,34–37,42</sup>, at-threshold<sup>15,30,39</sup>, or suprathreshold<sup>17,27,30,31,36,39,41,43,44</sup> intensities were used in rTMS protocols, ranging from 90% to 120% resting motor threshold (RMT) or motor threshold (MT) without specifying muscle activation status. TBS protocols, including iTBS and cTBS, used an 80% active motor threshold (AMT) as the stimulus intensity, except for one study using 80% RM $T^{28}$ .

Most studies used a single-session cross-sectional design to investigate the acute effects of rTMS or TBS. MEP amplitude was the most commonly used outcome measure to capture brain physiology17–22,27–29,31–33,46,47,49, while some studies reported the neuromodulatory effects with other physiological parameters such as MEP latency<sup>17,27</sup>, RMT<sup>27-29</sup>, AMT<sup>29</sup>, short-interval intracortical inhibition<sup>18</sup>, intracortical facilitation<sup>18</sup>, and motor map<sup>28</sup>. Behavior outcomes measuring cognitive function were used in two rTMS studies<sup>15,16</sup>. Some studies showed that neuromodulatory effects were less observed in Met allele carriers compared to Val/Val homozygotes<sup>17,18,22,27,32</sup>. Val/Val homozygotes

demonstrated more reliable neuromodulatory effects (excitatory or inhibitory) than Met allele carriers<sup>21,22,26</sup>. Alterations in behaviors measured by cognitive performance were evident in Val/Val homozygotes but not in Met allele carriers<sup>15,16</sup>. However, 47% of the studies in healthy individuals did not observe differences in neuromodulatory effects between Val/Val homozygotes and Met allele carriers, of which one study used rTMS<sup>31</sup>, seven studies used iTBS<sup>20,28,29,31,46,47,49</sup>, and three studies used  $cTBS^{29,33,46}$ .

#### *Stroke*

In stroke, three studies used high-frequency (10 Hz) rTMS at the ipsilesional M1<sup>35,36,42</sup>; two used low-frequency rTMS at the contralesional M1<sup>34,37</sup>; one used iTBS at the ipsilesional M1<sup>38</sup>; and two used cTBS at the right  $M1^{23,24}$ . Only one study targeted the right DLPFC with low-frequency rTMS<sup>30</sup>. Neuromodulatory effects on CSE were greater in Val/Val homozygotes compared to Met allele carriers<sup>23,36</sup>. Motor impairments of the upper limb measured by the Fugl Meyer Assessment and Box and Block Test were improved with excitatory high-frequency rTMS applied to the ipsilesional M1 in Val/Val homozygotes compared to Met allele carriers<sup>35,42</sup>, which was not observed with inhibitory lowfrequency rTMS applied to the contralesional  $M^{37}$ . Inhibitory cTBS reduced aphasia more in Val/Val homozygotes than Val/Met heterozygotes<sup>24</sup>. However, *BDNF* polymorphism has no impact on the CSE, *BDNF* concentration, and cognitive symptoms following low-frequency rTMS<sup>30,34</sup> or iTBS<sup>38</sup> in stroke.

#### *Depression*

All three studies on depression stimulated the DLPFC, and two studies targeted the left<sup>39,43</sup> while one targeted the right DLPFC<sup>44</sup>. Low-frequency rTMS<sup>43,44</sup>, high-frequency rTMS<sup>39,43</sup>, and iTBS<sup>39</sup> were used in these studies on depression. Stimulation intensities ranged from 100% to 110% RMT in rTMS studies<sup>39,43,44</sup>. A total of five to 10 sessions were administered with the number of stimulation stimuli ranging from 300 to 1800 per session. All rTMS studies showed more improvement in depression symptoms (measured by the Hamilton Depression Rating Scale) in Val/Val homozygotes than Met allele carriers<sup>39,43,44</sup>, whereas *BDNF* polymorphisms did not affect the change of depression symptoms following iTBS<sup>39</sup>.

#### *Other Disorders*

In studies on disorders other than stroke or depression, iTBS or cTBS was used on the left M1 of the FD $l^{25,26,40}$ . Two studies used iTBS<sup>45</sup> or cTBS<sup>50</sup> targeting the cerebellum, and one used highfrequency rTMS on the left  $DLPFC<sup>41</sup>$ . There were various outcome measures used to capture the neuromodulatory effects of rTMS and TBS, including physiological measures such as MEP amplitudes

and RMT, and behavioral or clinical measures of symptoms. One study in Parkinson's Disease with levodopa-induced dyskinesias<sup>50</sup> and another study in Spinocerebellar Ataxia 38<sup>45</sup> demonstrated greater neuromodulatory responses on serum *BDNF* with Val/Val homozygotes compared to Val/Met heterozygotes. Nonetheless, studies on Gilles de la Tourette syndrome and Spinocerebellar Ataxia 38 did not find different responses to TBS in clinical symptoms and MEP amplitudes between Val/Val homozygotes and Met allele carriers<sup>40,45</sup>. In this systematic review, only one study demonstrated greater neuromodulatory effects in Met allele carriers than Val/Val homozygotes after pooling the data from Alzheimer's disease. Type-2 diabetes mellitus, and controls<sup>26</sup>. Val/Met heterozygotes may result in more variability in the response to neuromodulation, which is consistent with the finding of another study in healthy individuals $^{21}$ .

#### **DISCUSSION**

This systematic review investigated the impact of *BDNF* genotypes, including the rs6265 and rs56164415, on the response to rTMS or TBS in the literature of human research. There was high heterogeneity in the research methodology across studies. 12 out of 23 (52.2%) of the rTMS or TBS protocols in healthy individuals demonstrated greater neuromodulatory effects with rTMS or TBS on neurophysiological measures such as MEP amplitude and behavioral measures of cognitive performance, in Val/Val homozygotes than Met allele carriers. 3 out of 10 (30.0%) protocols in stroke showed greater neuromodulatory effects on physiological measures like MEP amplitude or peripheral *BDNF* serum concentration, and another 30% of protocols showed more improvement in clinical outcomes with symptom improvement in Val/Val homozygotes compared to Met allele carriers. 4 out of 5 protocols in depression demonstrated more improvement in clinical outcomes with symptom improvement in Val/Val homozygotes compared to Met allele carriers. 11 out of 23 (47.8%) rTMS or TBS protocols in healthy individuals and 4 out of 10 (40.0%) protocols in stroke did not demonstrate different responses to rTMS or TBS in any outcome measures with the Val66Met polymorphism. The impact of *BDNF* Val66Met polymorphisms on other disorders was mixed.

#### **4.1 Dosage**

Determining appropriate dosage in the use of neuromodulation has been challenging due to a lack of standard definition of dosage<sup>51</sup>. The total number of pulses is the most common method of determining the dosage of TMS, while other parameters, such as stimulation intensity, stimulation frequency, and trial session number, contribute to the dose-response algorithm<sup>51-53</sup>. To date, the interaction between *BDNF* polymorphism and dosage of TMS has not been systematically investigated. Dosage can be discussed in two categories in the studies included in this systematic review: 1) immediate effect with a

single session of neuromodulation and 2) therapeutic effect with multiple neuromodulation sessions. All studies in healthy individuals were designed to investigate the immediate effect of rTMS/TBS with a single session, and the number of stimuli ranged from 250 to 1500. Five protocols for stroke and five protocols for other disorders used a single-session design, with the number of stimuli ranging from 600 to 1000. Single-session rTMS/TBS has not been shown to consistently modulate CSE in healthy individuals<sup>54</sup>. Similarly, the current systematic review also showed that the number of stimuli did not appear to contribute to the differences observed between *BDNF* genotypes with the immediate aftereffects of rTMS/TBS.

For multiple-session studies, five protocols for stroke, five protocols for depression, and two protocols for other disorders used five to 22 sessions to build up therapeutic effects with rTMS/TBS. There was high variability in the total number of stimuli used across these studies, between 2000 and 27000. Surprisingly, a lower total number of stimuli (10000 or less) appeared to be associated with differences observed in MEP amplitude and clinical outcomes between *BDNF* genotypes<sup>35,42-44</sup>, whereas a larger total number of stimuli (more than 10000) was associated with insignificant between-genotype differences<sup>30,34,37,39,45</sup>. It is possible that the influence of the *BDNF* polymorphism can be overcome by increasing the dosage with a large total number of stimuli to achieve the modulatory effects. However, *BDNF* polymorphism effects were not attenuated by higher dosages from increased stimulation intensity (100% RMT or higher)<sup>15,17,27,36,39,41,43,44</sup>.

#### **4.2 Forms of rTMS**

Theta burst stimulation, a modified form of rTMS, generates more substantial neuromodulatory effects in modulating CSE and synaptic plasticity than conventional  $rTMS<sup>2,55</sup>$ . It has been shown that the iTBS leads to longer-lasting increased CSE than high-frequency rTMS. Similarly, cTBS leads to longerlasting decreased CSE than low-frequency rTMS, although the effects are less consistent than iTBS $^2$ . A previous systematic review and meta-analysis examined how *BDNF* polymorphism influenced TBS effects and demonstrated larger effect sizes in Val/Val homozygotes. Met allele carriers, on the other hand, demonstrated variable results in response to TBS<sup>53</sup>. Two studies included in the current systematic review demonstrated variable findings in Met allele carriers and also used  $TBS^{21,26}$ . In studies with both rTMS and TBS protocols, one study in healthy individuals did not find *BDNF* polymorphism to impact CSE with either protocol<sup>31</sup>, whereas another study in depression showed that the depression symptoms reduced in Val/Val homozygotes but not Met allele carriers only with rTMS<sup>39</sup>. Overall, *BDNF* polymorphism influences response to neuromodulation in 14 out of 19 studies in rTMS

and 14 out of 26 studies in TBS. It is possible that the impact of the *BDNF* polymorphism could be attenuated by a modified yet intensive form of rTMS.

# **4.3 Excitatory versus Inhibitory Protocols**

There were conflicting findings on the consistency in modulating CSE with the excitatory versus inhibitory protocols in  $rTMS<sup>56</sup>$  and TBS<sup>53,57</sup>. There are known demographic and personal factors contributing to the neuromodulatory effects of long-term depression and long-term potentiation, including *BDNF* polymorphism9,58. In the current systematic review, the *BDNF* polymorphism effect was evident in similar percentages of studies in excitatory and inhibitory protocols. Overall, 16 out of 26 (61.5%) excitatory protocols (including high-frequency rTMS and iTBS) and 13 out of 19 (68.4%) inhibitory protocols (including low-frequency rTMS and cTBS) demonstrated a *BDNF* polymorphism effect on the response to neuromodulation. A previous systematic review, which only included healthy individuals, found approximately 20-30% of studies showed *BDNF* polymorphism-related changes in MEP<sup>59</sup>. When considering only the studies with healthy individuals in the current systematic review, 12 out of 23 (52.2%) protocols (excitatory: 6; inhibitory: 6) demonstrated *BDNF* polymorphism-related changes, which is considerably more than the previous systematic review<sup>59</sup>. This is possibly due to diverse statistical approaches, as the previous systematic review only considered the results of ANOVA to determine whether there was a *BDNF* polymorphism effect, while the current study included any statistical analyses showing differences in outcome measures between *BDNF* genotypes. Another systematic review and meta-analysis study in healthy individuals indicated that the effects of TBS (including both iTBS and cTBS) favored Val/Val homozygote over Met allele carriers, with the excitatory iTBS showing greater effect sizes<sup>53</sup>. While the current systematic review did not compare the effect sizes across the included studies, we expanded the scope to also include pathological populations beyond healthy individuals. A *BDNF* polymorphism effect was evident in 17 out of 22 (77.3%) protocols in pathological populations, with a marginally higher percentage in the excitatory (10 out of 12, 83.3%) compared to inhibitory (7 out of 10, 70%) protocols.

# **4.4 Methodological Considerations**

The methodologies and stimulation parameters used in the included studies were variable, likely due to a lack of consensus on optimal protocols in rTMS and TBS research. While the stimulation intensity, stimulation frequency, and pulse number used for TBS were consistent in most studies (80% AMT, 50 Hz, and 600 pulses, respectively), these three parameters were more variable in rTMS studies. Although the consistency of stimulation parameters reduced variability resulting from the neuromodulation device, of the 26 TBS protocols, only 14 studies (53.8%) showed significant *BDNF*

polymorphism effects. Personal factors such as symptom severity and demographics need to be taken into account as possible predictors of rTMS responsiveness.

Some commonly used outcome measures were not completely comparable given the different scales or units (e.g., MEP amplitude measured with the original unit in  $mV$ , percentage difference, or logtransformed; Hamilton rating scale for depression in 21 versus 17 items). Some studies segregated participants with Val/Met heterozygotes and Met/Met homozygotes as different genotypes, whereas others grouped them as Met allele carriers since there were often not enough data points with the Met/Met homozygotes. This precludes inferring the association between response to rTMS and Val/Met heterozygotes or Met/Met homozygotes.

As for stimulation sites, there were not enough studies using hotspots other than M1 in studies with healthy individuals, and thus whether brain region influences *BDNF* polymorphism effects remain inconclusive. In stroke, *BDNF* polymorphism effects were more apparent when targeting the ipsilesional M1 with high-frequency rTMS<sup>35,36,42</sup> compared to targeting the contralesional M1 with low-frequency rTMS<sup>30,34,37</sup> or ipsilesional iTBS<sup>38</sup>. Facilitating the post-stroke ipsilesional hemisphere or inhibiting the contralesional hemisphere was based on the interhemispheric imbalance model that hypothesizes asymmetric interhemispheric inhibition<sup>60</sup>. While administering low-frequency rTMS at the contralesional M1 and high-frequency rTMS at the ipsilesional M1 have been recommended by the most recent guidelines on the therapeutic use of rTMS<sup>7</sup>, it is possible that Met allele carriers are less responsive to high-frequency rTMS and therefore *BDNF* polymorphism should be considered while determining the rTMS protocol to enhance post-stroke motor recovery.

In the risk of bias assessments, lack of allocation concealment was often seen in the included studies, or there was no description of whether the investigators performing TMS-derived assessments were aware of the rTMS/TBS protocol. Other common biases included no blinding of the participants receiving different protocols of rTMS, and incomplete reports of stimulation parameters and the original values of group means in TMS-derived outcomes. Most of the studies (94.3%) did not report procedures or data in at least one domain of risk of bias assessment. These were rated as unclear risk of bias and further contributed to potential bias while interpreting the findings.

# **4.5 Limitations and Future Directions**

Some limitations of this systematic review are noted. First, only two studies examined the *BDNF* C270T polymorphism; therefore, there was not enough data to conclude the relationship between C270T

polymorphism and response to neuromodulation. Second, most included studies had small sample sizes of less than 50 participants. It is possible that some studies were underpowered with insignificant differences in outcome measures with classification according to *BDNF* genotypes or assignments to receive different rTMS protocols. Third, while *BDNF* polymorphism as a contributing factor to rTMS modulatory effects was widely studied in healthy individuals, there were insufficient publications in people with medical conditions. Quantitative data analysis was limited by the small number of studies, heterogeneity of patient characteristics, unretrievable data of key parameters, and inconsistency of rTMS protocols. Future studies are warranted to explore interactions between *BDNF* polymorphism and rTMS parameters and dosages while controlling participant-specific factors, such as symptom severity, in populations with medical conditions.

# **REFERENCES**

- 
- 1. Experimential magnetic stimulation (rTMS). Clinical Neurophysiology vol. 125 2150–220<br>
1. Experiment at https://doi.org/10.1016/j.clinph.2014.05.021 (2014).<br>
2. Rossini, P. M. et al. Non-invasive electrical and magnetic transcraming transcramination (rthe prince retranscrate of the principal Mension), Preprint at https://doi.org/10.1016/j.clinph.2014.05.021 (2014).<br>Rossini, P. M. et al. Non-invasive electrical and magnetic stimulation of Rossini, P. M. et al. Non-invasive electrical and magnetic stimulationd, roots and peripheral nerves: basic principles and proceduresearch application. An updated report from an I.F.C.N. Comm<br>Neurophysiology **126**, 1071–11 2. Rossini, 1. Fit. et al. Non-invasive electrical and magnetic summation of the brain, spinal<br>cord, roots and peripheral nerves: basic principles and procedures for routine clinical an<br>research application. An updated rep
- 
- research application. An updated report from an I.F.C.N. Committee. *Clinical*<br>Neurophysiology **126**, 1071–1107 (2015).<br>Huang, Y. Z., Edwards, M. J., Rounis, E., Bhatia, K. P. & Rothwell, J. C. Theta burst<br>stimulation of t research application. An updated report. The Meurophysiology 126, 1071–1107 (2015).<br>Huang, Y. Z., Edwards, M. J., Rounis, E., Bhatia, K. P. & Rothwell, J. C. Theta bu<br>Huang, Y. Z., Edwards, M. J., Rounis, E., Bhatia, K. P. Neurophysiology 126, 1071–1107 (2015).<br>Huang, Y. Z., Edwards, M. J., Rounis, E., B<br>stimulation of the human motor cortex. N<br>Pellegrini, M., Zoghi, M. & Jaberzadeh, S. I<br>interindividual variability to noninvasive b<br>systemat stimulation of the human motor cortex. *Neuron* 45, (2005).<br>
4. Pellegrini, M., Zoghi, M. & Jaberzadeh, S. Biological and anatomical factors influe<br>
interindividual variability to noninvasive brain stimulation of the prima stimulation of the human motor cortex. Neuron 45, (2005).<br>Pellegrini, M., Zoghi, M. & Jaberzadeh, S. Biological and ana<br>interindividual variability to noninvasive brain stimulation o<br>systematic review and meta-analysis. Re
- 
- 
- variability in response to non-invasive brain stimulation paradigms. *Brain Stimul* 7, (2014).<br>
6. Krause, B. & Kadosh, R. C. Not all brains are created equal: The relevance of individual<br>
differences in responsiveness to
- interindividual variability to noninvasive brain stimulation of the primary motor cortex:<br>
systematic review and meta-analysis. Rev Neurosci 29, (2018).<br>
5. López-Alonso, V., Cheeran, B., Río-Rodríguez, D. & Fernández-Delsystematic review and meta-analysis. *Rev Neurosci* 29, (2018).<br>López-Alonso, V., Cheeran, B., Río-Rodríguez, D. & Fernández-Del-Olmo, M. Inter-indivious variability in response to non-invasive brain stimulation paradigms. systematic review and meta-analysis. Hev Neurosci 29, (2016).<br>López-Alonso, V., Cheeran, B., Río-Rodríguez, D. & Fernández-I<br>variability in response to non-invasive brain stimulation paradig<br>Krause, B. & Kadosh, R. C. Not variability in response from invasive brain simulation paradigms. Brain control in the relevance of individual<br>differences in responsiveness to transcranial electrical stimulation. Frontiers in Systems<br>Neuroscience vol. 8 differences in responsiveness to transcranial electrical stimulation. *Frontiers in System*<br> *Neuroscience* vol. 8 Preprint at https://doi.org/10.3389/fnsys.2014.00025 (2014).<br>
7. Lefaucheur, J. P. et al. Evidence-based gu differences in responsiveness to transcrime vecellences in response to transcranial magnetic stimulation (rTMS): An update (2014–2018). *Clinical Neurophysiologary* Lefaucheur, J. P. et *al.* Evidence-based guidelines on t Neuroscience vol. 8 The finite and guidelines on the the repetition and the distancheur, J. P. et al. Evidence-based guidelines on the therapeutic server for repetitive and magnetic stimulation (rTMS): An update (2014–2018 7. Extractionial magnetic stimulation (rTMS): An update (2014–2018). Clinical Neurophys<br>
vol. 131 474–528 Preprint at https://doi.org/10.1016/j.clinph.2019.11.002 (2020).<br>
8. Kotlega, D., Peda, B., Zembroń-Łacny, A., Gotab transcramia transports csimulation (rtrin); An update (2014–2016), cominent transcreament in Rodinga, D., Peda, B., Zembroń-Łacny, A., Gotab-Janowska, M. & Nowacki, P. The role of brain-derived neurotrophic factor and its Kotlega, D., Peda, B., Zembroń-Łacny, A., Gołąb-Janowska, M. & Nowacki, P. The<br>brain-derived neurotrophic factor and its single nucleotide polymorphisms in stro<br>patients. *Neurol Neurochir Pol* **51**, 240–246 (2017).<br>Suppa,
- 
- brain-derived neurotrophic factor and its single nucleotide polymorphisms in stroke<br>patients. Neurol Neurochir Pol 51, 240–246 (2017).<br>Suppa, A. & Cheeran, B. Further insights into the effect of BDNF genotype on non-invasi patients. *Neurol Neurochir Pol* 51, 240–246 (2017).<br>Suppa, A. & Cheeran, B. Further insights into the effect of BDNF genotype on non-inv<br>brain stimulation. *Clin Neurophysiol* 126, 1281–1283 (2015).<br>Saghazadeh, A., Esfaha paticints. Neurol Metaborii 11 of 31, 240–240 (2017).<br>Suppa, A. & Cheeran, B. Further insights into the eff<br>brain stimulation. *Clin Neurophysiol* **126**, 1281–128<br>Saghazadeh, A., Esfahani, S. A. & Rezaei, N. Genetii<br>brain brain stimulation. Clin Neurophysiol **126**, 1281–1283 (2015).<br>
10. Saghazadeh, A., Esfahani, S. A. & Rezaei, N. Genetic polymorphisms and the adequacy of<br>
brain stimulation: state of the art. Expert Review of Neurotherapeu Brain stimulation. On Treatophysiol 126, 1281–1283 (2015).<br>Saghazadeh, A., Esfahani, S. A. & Rezaei, N. Genetic polymor<br>brain stimulation: state of the art. Expert Review of Neurothe,<br>https://doi.org/10.1080/14737175.2016.
- 
- 10. Interaction: State of the art. Expert Review of Neurotherapeutics vol. 16 Preprint at<br>
https://doi.org/10.1080/14737175.2016.1194202 (2016).<br>
11. McHughen, S. A. et al. BDNF val66met polymorphism influences motor syste brain stimulation: state of the art. Expert Review of Neurothelpoints for, it is respirated in the artists://doi.org/10.1080/14737175.2016.1194202 (2016).<br>McHughen, S. A. et al. BDNF val66met polymorphism influences motor McHughen, S. A. et al. BDNF val66met polymorphism influte human brain. Cerebral Cortex 20, (2010).<br>Bath, K. G. & Lee, F. S. Variant BDNF (Val66Met) impact of Cognitive, Affective and Behavioral Neuroscience vol. 6 P<br>https: 11. McHughen, 13. A. et al. BDNI Valorine polymorphism influences motor system function in<br>
12. Bath, K. G. & Lee, F. S. Variant BDNF (Val66Met) impact on brain structure and function.<br>
Cognitive, Affective and Behavioral the human bram. Cerebral Cortex 20, (2010).<br>Bath, K. G. & Lee, F. S. Variant BDNF (Val66M:<br>Cognitive, Affective and Behavioral Neuroscie<br>https://doi.org/10.3758/CABN.6.1.79 (2006).<br>Watanabe, Y., Nunokawa, A. & Someya, T. A Cognitive, Affective and Behavioral Neuroscience vol. 6 Preprint at<br>
https://doi.org/10.3758/CABN.6.1.79 (2006).<br>
13. Watanabe, Y., Nunokawa, A. & Someya, T. Association of the BDNF C270T polymorphisn<br>
with schizophrenia:
- 
- 
- Cognitive, Affective and Behavioral Neuroscience vol. 61 reprint at<br>https://doi.org/10.3758/CABN.6.1.79 (2006).<br>Watanabe, Y., Nunokawa, A. & Someya, T. Association of the BDNF<br>with schizophrenia: Updated meta-analysis. *Ps* Watanabe, Y., Nunokawa, A. & Someya, T. As<br>Watanabe, Y., Nunokawa, A. & Someya, T. As<br>with schizophrenia: Updated meta-analysis. *H*<br>Higgins, J. P. T. *et al*. The Cochrane Collabora<br>randomised trials. *BMJ* **343**, (2011). with schizophrenia: Updated meta-analysis. *Psychiatry Clin Neurosci* **67**, (2013).<br>
14. Higgins, J. P. T. et al. The Cochrane Collaboration's tool for assessing risk of bias in<br>
15. Tulviste, J. et al. BDNF polymorphism i whis schepmental. Optated meta-analysis. Psychiatry Christensol. (2010).<br>Higgins, J. P. T. et al. The Cochrane Collaboration's tool for assessing risk of bias<br>randomised trials. *BMJ* **343**, (2011).<br>Tulviste, J. et al. BDN 14. Higgins, J. P. P. Etad. The Cochrane Collaboration's tool for assessing risk of bias in<br>
randomised trials. *BMJ* **343**, (2011).<br>
15. Tulviste, J. et al. BDNF polymorphism in non-veridical decision making and different randomised trials. *BMJ* 343, (2011).<br>Tulviste, J. et al. BDNF polymorphist<br>effects of rTMS. *Behavioural Brain R*<br>Abellaneda-Pérez, K. et al. BDNF Va<br>following rTMS-induced memory im
- 15. Tutviste, J. et al. BDNF polymorphism in non-veridical decision making and differential<br>effects of rTMS. Behavioural Brain Research **364**, (2019).<br>16. Abellaneda-Pérez, K. et al. BDNF Val66Met gene polymorphism modulat effects of rims. Behavioural Brain Research 334, (2019).<br>Abellaneda-Pérez, K. e*t al*. BDNF Val66Met gene polymor<br>following rTMS-induced memory impairment. *Sci Rep* 12, 16. Abelianced Terez, K. et al. BDNF Valoomet gene polymorphism modulates brain activity<br>following rTMS-induced memory impairment. Sci Rep 12, (2022). following rtms-induced memory impairment. Servic $p$  12, (2022).

- 
- 
- 17. Jayasekeran, V. et al. Valorietti biannain-derived incordiginal tactor affects summation-<br>
18. Andrews, S. C. et al. Intensity Matters: High-intensity Interval Exercise Enhances Mott<br>
Cortex Plasticity More Than Modera induced plasticity in the minimi pharyngeal motor cortex. Ossetto from Cortex Plasticity More Than Moderate Exercise. Cerebral Cortex 30, (2020).<br>Cortex Plasticity More Than Moderate Exercise. Cerebral Cortex 30, (2020).<br>J 18. Andrews, S. O. et al. Intensity Material Exercise. *Cerebral Cortex* **30**, (2020).<br>
19. Jannati, A., Block, G., Oberman, L. M., Rotenberg, A. & Pascual-Leone, A. Interindividua<br>
variability in response to continuous th Solitical A., Block, G., Oberman, L. M., Rotenberg, A. & Pascual-Leone, A. In<br>Jannati, A., Block, G., Oberman, L. M., Rotenberg, A. & Pascual-Leone, A. In<br>Veurophysiology 128, (2017).<br>Gomes-Osman, J. et al. The effects of
- 
- 
- 
- variability in response to continuous theta-burst stimulation in healthy adults. Clinical<br>
Neurophysiology **128**, (2017).<br>
20. Gomes-Osman, J. et al. The effects of exercise on cognitive function and brain plasticity<br>
feas variability in response to continuous theta-burst stimulation in healthy adults. Clinical<br>Comes-Osman, J. et al. The effects of exercise on cognitive function and brain plasticit<br>feasibility trial. Restor Neurol Neurosci 3 Neurophysiology 120, (2017).<br>Gomes-Osman, J. et al. The ef<br>feasibility trial. *Restor Neurol*<br>Harvey, D. Y. et al. Variability i<br>Intensity With BDNF Val66Met<br>Jannati, A. et al. Test-retest re<br>*Front Neurosci* **13**, (2019). 20. Gomes-Osman, J. et al. Restor Neurol Neurosci 35, (2017).<br>
21. Harvey, D. Y. et al. Variability in CTBS Aftereffects Attributed to the Interaction of Stimulus<br>
Intensity With BDNF Val66Met Polymorphism. *Front Hum Neur* Frankly that. Hostor Mediot Mediosocr 35, (2017).<br>Harvey, D. Y. et al. Variability in cTBS Aftereffects A<br>Intensity With BDNF Val66Met Polymorphism. *Fror*<br>Jannati, A. et al. Test-retest reliability of the effects<br>Front Ne Intensity With Disk Victor-Ict of Cymorphism. Front Hum Neurosci 15, (2021).<br>Iannati, A. de al. Test-retest reliability of the effects of continuous theta-burst s<br>Front Neurosci 13, (2019).<br>Parchure, S. et al. Brain-Derive From Neurosci 13, (2019).<br>Parchure, S. et al. Brain-De<br>Response to Continuous T<br>Neuromodulation **25**, (202.<br>Dresang, H. C. et al. Genet<br>Post-Stroke Language Rec<br>Jannati, A. et al. Modulatio<br>stimulation in adults with a<br>Fri
- 
- 
- 21. Harvey, D. F. For al. Variability in Chinamic Statements Attributed of the intensity With BDNF Val66Met Polymorphism. *Front Hum Neurosci* **15**, (2021).<br>22. Jannati, A. et al. Test-retest reliability of the effects of Front Neurosci 13, (2019).<br>
Front Neurosci 13, (2019).<br>
23. Parchure, S. et al. Brain-Derived Neurotrophic Factor Gene Polymorphism Predicts<br>
Response to Continuous Theta Burst Stimulation in Chronic Stroke Patients.<br>
Neur 23. Priestigate Continuous Theta Burst Stimulation in Chronic Stroke Patients.<br>
Response to Continuous Theta Burst Stimulation in Chronic Stroke Patients.<br>
Neuromodulation 25, (2022).<br>
24. Dresang, H. C. et al. Genetic and Neuromodulation 25, (2022).<br>Dresang, H. C. et al. Genetic and Neurophysiological Biomarkers of Neuropla<br>Post-Stroke Language Recovery. Neurorehabil Neural Repair 36, (2022).<br>Jannati, A. et al. Modulation of motor cortical
- 
- Neuromodulation 23, (2022).<br>Dresang, H. C. et al. Genetic a<br>Post-Stroke Language Recove<br>Jannati, A. et al. Modulation o<br>stimulation in adults with auti<br>Fried, P. J., Jannati, A., Davila-<br>paired-pulse, and intermitten<br>and A 24. Dressing, H. O. et al. Detection and Neurophysiological antimizers of recomplessively informed<br>
25. Jannati, A. et al. Modulation of motor cortical excitability by continuous theta-burst<br>
stimulation in adults with aut Fost-Stroke Language Recovery. Meanotenability meant ringali out, (2022).<br>Jannati, A. et al. Modulation of motor cortical excitability by continuous t<br>stimulation in adults with autism spectrum disorder. Clinical Neurophys 22. Janual, A. et al. Interaction of Motor Cortical excitability by commuted streat bursts string and Alzheimer's disease. Front Aging Neurosci 9, (2017).<br>
26. Fried, P. J., Jannati, A., Davila-Pérez, P. & Pascual-Leone, A stimulation in adults with automic spectrum usions of Fried, P.J., Jannati, A., Davila-Pérez, P. & Pascual-Leone, A. Reproducibility of single-pulse, paired-pulse, and intermittent theta-burst TMS measures in healthy aging paired-pulse, and intermittent theta-burst TMS measures in healthy aging, Type-2 diabetes,<br>and Alzheimer's disease. *Front Aging Neurosci* **9**, (2017).<br>27. Hwang, J. M., Kim, Y. H., Yoon, K. J., Uhm, K. E. & Chang, W. H. D and Alzheimer's disease. *Front Aging Neurosci* 9, (2017).<br>Hwang, J. M., Kim, Y. H., Yoon, K. J., Uhm, K. E. & Chang, W. H. Different responses to<br>facilitatory rTMS according to BDNF genotype. *Clinical Neurophysiology* **1**
- 
- and Alzheimer's disease. Front Aging Neurosci 9, (2017).<br>Hwang, J. M., Kim, Y. H., Yoon, K. J., Uhm, K. E. & Chang, V<br>facilitatory rTMS according to BDNF genotype. *Clinical Nee, M. et al.* Interaction of Motor Training an Facilitatory rTMS according to BDNF genotype. *Clinical Neurophysiology* **126**, (2015).<br>
28. Lee, M. et al. Interaction of Motor Training and Intermittent Theta Burst Stimulation in<br>
Modulating Motor Cortical Plasticity: facilitatory rinks according to BDNF genotype. Climical Neurophysiology 126, (2015).<br>Lee, M. et al. Interaction of Motor Training and Intermittent Theta Burst Stimulation in<br>Modulating Motor Cortical Plasticity: Influence 28. Lee, The cast interaction of Protof Training and intermittent Theta Burst Stimulation interactions.<br>
29. Guerra, A. et al. Gamma-transcranial alternating current stimulation and theta-burst<br>
3. (2013).<br>
29. Guerra, A. 9, (2019).<br>Guerra, A.<br>stimulatio<br>(2020).<br>Lu, H., Zhann post-st<br>(2015).<br>Li Voti, P.<br>in healthy Cheeran,<br>BDNF) mc<br>586, (2008<br>McDonne 29. Guerra, R. et al. Gamma-transcranial alternating current stimulation and theta-burst<br>
29. Eu, H., Zhang, T., Wen, M. & Sun, L. Impact of repetitive transcranial magnetic stimulation controls.<br>
20. Lu, H., Zhang, T., We stimulation: inter-subject variability and the rote of BDNY : Camber Wearbpingsloogy 101,<br>Lu, H., Zhang, T., Wen, M. & Sun, L. Impact of repetitive transcranial magnetic stimulation<br>on post-stroke dysmnesia and the role of (2020).<br>Lu, H., 2<br>on post<br>(2015).<br>Li Voti,<br>in healt<br>Cheera<br>BDNF) r<br>586, (20<br>of aerol<br>Mirows<br>polymo<br>outcom
- 
- Modulating Frotor Cortical Plasticity: Initiating current stimulation and theta-burst<br> **8.** (2013).<br>
Guerra, A. et al. Gamma-transcranial alternating current stimulation and theta-burst<br>
stimulation: inter-subject variabil 30. Lu, Voltaire de and the role of BDNF Val66Met SNP. Med Sci Monit 21, 761–8<br>31. Li Voti, P. et al. Correlation between cortical plasticity, motor learning and BDNF genotype<br>in healthy subjects. Exp Brain Res 212, (2011) on post-stroke dysinmesia and the role of BDNN values leart, the set friend 21, 761–9<br>(2015).<br>Li Voti, P. et al. Correlation between cortical plasticity, motor learning and BDNF genoty<br>in healthy subjects. Exp Brain Res 21 ,<br>Li Voti,<br>in healt<br>Cheera<br>BDNF) **1**<br>**586**, (20<br>McDoni<br>of aerot<br>Mirows<br>polymo<br>outcom 31. Li Voti, 1. Ca. Correlation between correlation between correlations and BDNF genotype in healthy subjects. Exp Brain Res 212, (2011).<br>32. Cheeran, B. et al. A common polymorphism in the brain-derived neurotrophic fact in heading subjects. Exp Brain Res 212, (2011).<br>Cheeran, B. et al. A common polymorphism in<br>BDNF) modulates human cortical plasticity and<br>586, (2008).<br>McDonnell, M. N., Buckley, J. D., Opie, G. M., R<br>of aerobic exercise pr
- 
- SECTED BDNF) modulates human cortical plasticity and the response to rTMS. Journal of Physiology<br>
33. McDonnell, M. N., Buckley, J. D., Opie, G. M., Ridding, M. C. & Semmler, J. G. A single bout<br>
of aerobic exercise promot B586, (2008).<br>McDonnell, M. N., Buckley, J. D., Opie, G. M., Ridding, M. C. & Semmler, J. G. A single bout<br>of aerobic exercise promotes motor cortical neuroplasticity. *J Appl Physiol* **114**, (2013).<br>Mirowska-Guzel, D. et France<br>McDonnell,<br>of aerobic ex<br>Mirowska-Gi<br>polymorphis<br>outcome aft of aerobic exercise promotes motor cortical neuroplasticity. J Appl Physiol 114, (2013).<br>34. Mirowska-Guzel, D. et al. Association between BDNF-196 G>A and BDNF-270 C>T<br>polymorphisms, BDNF concentration, and rTMS-supported of aerobic exercise promotes motor cortical neuroplasticity. J Appl Physiol 114, (2013).<br>Mirowska-Guzel, D. et al. Association between BDNF-196 G>A and BDNF-270 C>T<br>polymorphisms, BDNF concentration, and rTMS-supported lon 34. Mirowska-Guzel, D. et al. Association between BDNF-196 G>A and BDNF-270 C>T<br>polymorphisms, BDNF concentration, and rTMS-supported long-term rehabilitation<br>outcome after ischemic stroke. NeuroRehabilitation 32, (2013). program productions, Branch concentration, and recomplementary control and reduced outcome after ischemic stroke. NeuroRehabilitation 32, (2013). outcome after ischemic stroke. Neuronenabilitation 32, (2013).

- 
- 
- 
- 
- 33. Chang, W. H. et al. Padictive roles, D. M. & Chang, W. H. BDNF genotype influence the efficacy of rTMS in stroke patients. Neurosci Lett 594, (2015).<br>37. Niimi, M. et al. Role of brain-derived neurotrophic factor in be stroke patients. *Brain Stimut 7*, (2014).<br>Uhm, K. E., Kim, Y. H., Yoon, K. J., Hwarefficacy of rTMS in stroke patients. *Neu*<br>Niimi, M. e*t al*. Role of brain-derived ne<br>transcranial magnetic stimulation for u<br>(2016).<br>Di efficacy of rTMS in stroke patients. *Neurosci Lett* **594**, (2015).<br>
37. Niimi, M. et al. Role of brain-derived neurotrophic factor in beneficial effects of repetitive<br>
transcranial magnetic stimulation for upper limb hemi efficacy of Firms in stroke patients. Mearoscribett 394, (2015).<br>Niimi, M. et al. Role of brain-derived neurotrophic factor in be<br>transcranial magnetic stimulation for upper limb hemiparesis<br>(2016).<br>Di Lazzaro, V. et al. V 17. Strain, First and Note of Brain-derived neurotrophic factor in beneficial effects of repetitive<br>
17. Bullazzaro, V. et al. Val66Met BDNF gene polymorphism influences human motor cortex<br>
18. Di Lazzaro, V. et al. Val66M transcrume magnetic stimulation for upper limb hemiparesis after stroke. PLoS One 11,<br>(2016).<br>Di Lazzaro, V. et *al.* Val66Met BDNF gene polymorphism influences human motor cortex<br>plasticity in acute stroke. *Brain Stimul* (Derrey).<br>Di Lazza<br>plastici<br>Cheng,<br>polymo<br>monoth<br>(2022).<br>Marsili,<br>Tourett<br>Su, X. e<br>Functio<br>Neurop<br>Chang, 38. Diezzzaro, v. et al. Brokel-Brain Stimul 8, 92–96 (2015).<br>
39. Cheng, C. M. et al. Predictive roles of brain-derived neurotrophic factor Val66Met<br>
polymorphism on antidepressant efficacy of different forms of prefronta plasticity in acute stroke. *Brain Stimula 8, 92–99* (2019).<br>Cheng, C. M. *et al.* Predictive roles of brain-derived neu<br>polymorphism on antidepressant efficacy of different for<br>monotherapy: A randomized, double-blind, sha 39. Cheng, C. M. et al. 1 et al. Predictive Total of different forms of prefrontal brain still<br>polymorphism on antidepressant efficacy of different forms of prefrontal brain still<br>monotherapy: A randomized, double-blind,
- 
- 
- monotherapy: A randomized, double-blind, sham-controlled study. *J Affect Disord* 297,<br>(2022).<br>Marsili, L. *et al.* BDNF and LTP-/LTD-like plasticity of the primary motor cortex in Gilles de la<br>Tourette syndrome. *Exp Brai* monotionally: A randomized, double-blind, sham-controlled study. J Ameet Disord 297,<br>(2022).<br>Marsili, L. et al. BDNF and LTP-/LTD-like plasticity of the primary motor cortex in Gilles d<br>Tourette syndrome. *Exp Brain Res* 2 (2022).<br>Marsili,<br>Tourett<br>Su, X. e<br>Functio<br>*Neurop*<br>Chang,<br>respons<br>subacu<br>Bocchic<br>FTMS tre<br>Krstić, J<br>prefron 44. Kitaliant, L. et al. Den variables and Linear Correst in Gilles (2017).<br>
41. Su, X. et al. Neuronavigated Repetitive Transcranial Stimulation Improves Neurocognitive<br>
41. Su, X. et al. Neuronavigated Repetitive Transcr Fourcite syndrome. Exp Brammes 233, (2017).<br>Su, X. et al. Neuronavigated Repetitive Transcra<br>Functioning in Veterans with Schizophrenia: Al<br>Neuropharmacol 21, 142–150 (2023).<br>Chang, W. H., Uhm, K. E., Shin, Y. II, Pascual-41. Su, Y. et al. 1911. Herapid Computer Transcription in the repetitive Transcription in provides Neuropharmacol 21, 142–150 (2023).<br>42. Chang, W. H., Uhm, K. E., Shin, Y. II, Pascual-Leone, A. & Kim, Y. H. Factors influe Functioning in vectains with Schizophielia. A Possible Role of BDNF Polymorphism. Curr<br>Reuropharmacol 21, 142–150 (2023).<br>Chang, W. H., Uhm, K. E., Shin, Y. II, Pascual-Leone, A. & Kim, Y. H. Factors influencing the<br>respon Neurophamacol 21, 142–150 (2023).<br>Chang, W. H., Uhm, K. E., Shin, Y. Il, P.<br>response to high-frequency repetitive<br>subacute stroke. Restor Neurol Neuro<br>Bocchio-Chiavetto, L. et al. 5-HTTLPR<br>rTMS treatment in drug resistant
- 
- Frace to high-frequency repetitive transcranial magnetic stimulation in patients with<br>subacute stroke. Restor Neurol Neurosci 34, (2016).<br>43. Bocchio-Chiavetto, L. et al. 5-HTILPR and BDNF Val66Met polymorphisms and respon subacute stroke. *Restor Neurol Neurosci* **34**, (2016).<br>Bocchio-Chiavetto, L. et al. 5-HTTLPR and BDNF Val66Met polymorphisms and responserTMS treatment in drug resistant depression. *Neurosci Lett* **437**, (2008).<br>Krstić, subacute stroke. Mestor Mediot Medioser 04, (2010).<br>Bocchio-Chiavetto, L. et al. 5-HTTLPR and BDNF Vale<br>rTMS treatment in drug resistant depression. Neuros<br>Krstić, J. et al. Low-frequency repetitive transcranial i<br>prefront 44. Bocchio Chiavetto, L. et al. 11 TMS treatment in drug resistant depression. Neuroscil Lett 437, (2008).<br>44. Krstić, J. et al. Low-frequency repetitive transcranial magnetic stimulation in the right<br>prefrontal cortex c rtrio acalment in anglessiant depression. We hosser Ectt 437, (2000).<br>Krstić, J. et al. Low-frequency repetitive transcranial magnetic stimulation<br>perfrontal cortex combined with partial sleep deprivation in treatment-r<br>de 44. Krstic, J. et al. Complined with partial sleep deprivation in treatment-resistant<br>depression: A randomized sham-controlled trial. Journal of ECT 30, (2014).<br>45. Sanna, A. et al. Therapeutic Use of Cerebellar Intermitte
- 
- 
- 
- depression: A randomized sham-controlled trial. Journal of ECT 30, (2014).<br>Sanna, A. et al. Therapeutic Use of Cerebellar Intermittent Theta Burst Stimulatia<br>a Sardinian Family Affected by Spinocerebellar Ataxia 38 (SCA 38 depression: A randomized sham-controlled trial. Journal of ECT 30, (2014).<br>Sanna, A. et al. Therapeutic Use of Cerebellar Intermittent Theta Burst Stim<br>a Sardinian Family Affected by Spinocerebellar Ataxia 38 (SCA 38). Cer 45. Sanna, A. et al. Branchetter Stronghere of Concernation and Transcration (1150)<br>
46. Mastroeni, C. et al. Brain-Derived Neurotrophic Factor - A Major Player in Stimulation-<br>
146. Mastroeni, C. et al. Brain-Derived Neur
- 
- 
- a commant runny successor by epimeocression reads as of cockretic Restoration Family in Mastroenii, C. et al. Brain-Derived neurotrophic Factor A Major Player in Stimulation-Induced Homeostatic Metaplasticity of Human Mo 46. Mastroeni, C. et al. Cerebellar Context Permier Tacking Induced Homeostatic Metaplasticity of Human Motor Cortex? PLoS One 8, (2013).<br>47. Antal, A. et al. Brain-derived neurotrophic factor (BDNF) gene polymorphisms sha matuced Friendostatic Friendostatic Mother (BDNF) gene polymorphisms shap<br>Antal, A. et al. Brain-derived neurotrophic factor (BDNF) gene polymorphisms shap<br>cortical plasticity in humans. *Brain Stimul* **3**, (2010).<br>Moliadz 47. Antal, A. et al. Brain-derived increasing metric (BDNF) gene polymorphisms shape<br>cortical plasticity in humans. Brain Stimul 3, (2010).<br>48. Moliadze, V., Fritzsche, G. & Antal, A. Comparing the efficacy of excitatory t
- cortical plasticity in humans. Brain Stimut 3, (2010).<br>Moliadze, V., Fritzsche, G. & Antal, A. Comparing the<br>stimulation methods measuring motor evoked poter<br>Antal, A. et al. BDNF Gene Polymorphisms and Moto<br>When Should We stimulation methods measuring motor evoked potentials. Neural Plast 2014, (2014).<br>49. Antal, A. et al. BDNF Gene Polymorphisms and Motor Cortical Plasticity in Healthy Hum<br>When Should We Consider It. *J* Neurosci Rehabil 1 stimulation incontinuation and Motor Corticulation measuring motor Corticulation measuring motor Corticulation measuring the When Should We Consider It. *J Neurosci Rehabit* 1, (2014).<br>When Should We Consider It. *J Neuros* 49. Mind, A. et al. Definite Consider It. J Neurosci Rehabil 1, (2014).<br>
So. Sanna, A. et al. Gerebellar continuous theta burst stimulation reduces levodopa-induced<br>
dyskinesias and decreases serum BDNF levels. Neurosci Le When Should We Consider R. 3 Neurosci Remark 1, (2014).<br>Sanna, A. et al. Cerebellar continuous theta burst stimulati<br>dyskinesias and decreases serum BDNF levels. *Neurosci L*.<br>Sabé, M. et al. Transcranial Magnetic Stimulat 50. Samin, A. et al. Cerebears serum BDNF levels. Neurosci Lert 716, (2020).<br>
Sabé, M. et al. Transcranial Magnetic Stimulation and Transcranial Direct Current<br>
Stimulation Across Mental Disorders: A Systematic Review and dyskinesias and decreases serum BDNF levels. Neuroscribert 716, (2020).<br>Sabé, M. et al. Transcranial Magnetic Stimulation and Transcranial Direct (<br>Stimulation Across Mental Disorders: A Systematic Review and Dose-Resp<br>Ana 51. Sabé, H. et al. Transcriance Highetic Stimulation and Transcriance Direct Current<br>Stimulation Across Mental Disorders: A Systematic Review and Dose-Response M<br>Analysis. JAMA Netw Open 7, (2024).<br>52. Yang, C. et al. Rep Analysis. JAMA Netw Open 7, (2024).<br>Yang, C. et al. Repetitive transcranial<br>Parkinson's disease: A Meta-analysis<br>https://doi.org/10.1002/brb3.1132 (2 52. Tang, O. et al. Repetitive transcranial magnetic stimulation therapy for motor recovery in<br>Parkinson's disease: A Meta-analysis. *Brain and Behavior* vol. 8 Preprint at<br>https://doi.org/10.1002/brb3.1132 (2018). Parkinson's disease: A Meta-analysis. *Brain and Behavior* vol. 8 Preprint at<br>https://doi.org/10.1002/brb3.1132 (2018). https://doi.org/10.1002/brb3.1132 (2018).

- 
- 
- stimulation in changing excitability of motor cortex: A systematic review and meta-anal<br> *Neurosci Biobehav Rev* 63, 43–64 (2016).<br>
54. Hiscock, A., Miller, S., Rothwell, J., Tallis, R. C. & Pomeroy, V. M. Informing dose-f Neurosci Biobehav Rev 63, 43–64 (2016).<br>Hiscock, A., Miller, S., Rothwell, J., Tallis, R. C. & Pomeroy, V. M. Informing dose-finding<br>studies of repetitive transcranial magnetic stimulation to enhance motor function: A<br>qual Neurosci Broberiav Rev 63, 43–64 (2016).<br>Hiscock, A., Miller, S., Rothwell, J., Tallis,<br>studies of repetitive transcranial magnetic<br>qualitative systematic review. Neuroreha.<br>Rachid, F. Safety and efficacy of theta-bu<br>disor studies of repetitive transcranial magnetic stimulation to enhance motor function: A<br>qualitative systematic review. Neurorehabil Neural Repair 22, (2008).<br>55. Rachid, F. Safety and efficacy of theta-burst stimulation in th qualitative systematic review. *Neurorehabil Neural Repair* 22, (2008).<br>Rachid, F. Safety and efficacy of theta-burst stimulation in the treatment of psychiatr<br>disorders: A review of the literature. *Journal of Nervous and* qualitative systematic review. Meal of chain Meal at Repair 22, (2000).<br>Rachid, F. Safety and efficacy of theta-burst stimulation in the treatme<br>disorders: A review of the literature. Journal of Nervous and Mental Dis<br>Prep
- 
- 
- disorders: A review of the literature. Journal of Nervous and Mental Disease vol. 205<br>
Preprint at https://doi.org/10.1097/NMD.0000000000000742 (2017).<br>
56. Prei, K. et al. Limited evidence for reliability of low and high disorders: A review of the literature. Determined the literature is a reprint at https://doi.org/10.1097/NMD.000000000000000742 (2017).<br>Preprint a https://doi.org/10.1097/NMD.000000000000000742 (2017).<br>Cortex. *Brain Res* 56. Prei, K. et al. Limited evidence for reliability of low and high reduction of theta Burst Stimulation<br>in Healthy Humans. *Brain Stimul 8*, 685–692 (2015).<br>58. Silverstein, W. K. et al. NEUROBIOLOGICAL PREDICTORS of RES in Healthy Humans. *Brain Stimul* **8**, 685–692 (2015).<br>
58. Silverstein, W. K. et al. NEUROBIOLOGICAL PREDICTORS of RESPONSE to DORSOLATERAL<br>
PREFRONTAL CORTEX REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION in<br>
DEPRESSION: A
- 
- Prei, K. *et al.* Limited evidence for reliability of low and high frequency<br>cortex. *Brain Res* **1820**, (2023).<br>Wischnewski, M. & Schutter, D. J. L. G. Efficacy and Time Course of Ti<br>in Healthy Humans. *Brain Stimul* **8**, cortex. *Brain Res* 1820, (2023).<br>Wischnewski, M. & Schutter, D.<br>in Healthy Humans. *Brain Stimu*<br>Silverstein, W. K. et al. NEUROP<br>PREFRONTAL CORTEX REPETIT<br>DEPRESSION: A SYSTEMATIC R<br>Sasaki, R. et *al.* Influence of bra<br>a in Healthy Humans. Brain Stimul 8, 685–692 (2015).<br>Silverstein, W. K. et al. NEUROBIOLOGICAL PREDIC<br>PREFRONTAL CORTEX REPETITIVE TRANSCRANIAL I<br>DEPRESSION: A SYSTEMATIC REVIEW. Depress Anx.<br>Sasaki, R. et al. Influence of b 58. SINVERTION, W. K. E. *d.* NEURODIOLOGICAL THEODIC STINULATION in<br>PREFRONTAL CORTEX REPETITIVE TRANSCRANIAL MAGNETIC STINULATION in<br>DEPRESSION: A SYSTEMATIC REVIEW. *Depress Anxiety* **32**, (2015).<br>59. Sasaki, R. *et al.* DEPRESSION: A SYSTEMATIC REVIEW. *Depress Anxiety* **32**, (2015).<br>Sasaki, R. *et al.* Influence of brain-derived neurotrophic factor genotype on short<br>afferent inhibition and motor cortex metabolites. *Brain Sci* **11**, (202 DET RESSION: A SYSTEMATIC REVIEW. Depress Anxiety **2**, (2015).<br>Sasaki, R. et al. Influence of brain-derived neurotrophic factor geno<br>afferent inhibition and motor cortex metabolites. *Brain Sci* **11**, (202<br>Boddington, L. J 59. Sasaki, R. et al. Initiation and motor cortex metabolites. Brain-derived neuron genotype on short-latency<br>afferent inhibition and motor cortex metabolites. Brain Sci 11, (2021).<br>Boddington, L. J. & Reynolds, J. N. J. T and interest inhibition and motor cortex includedness. Brain Scr 11, (2021).<br>Boddington, L. J. & Reynolds, J. N. J. Targeting interhemispheric inhibit<br>neuromodulation to enhance stroke rehabilitation. *Brain Stimulation* v neuromodulation to enhance stroke rehabilitation. *Brain Stimulation vol.* 10 Pr<br>https://doi.org/10.1016/j.brs.2017.01.006 (2017).<br>https://doi.org/10.1016/j.brs.2017.01.006 (2017). neuromodulation to enhance stroke rehabilitation. Brain Sambadion vol. 10 Preprint at<br>https://doi.org/10.1016/j.brs.2017.01.006 (2017). https://doi.org/10.1016/j.brs.2017.01.006 (2017).

# **FIGURE CAPTIONS**

**Figure 1.** PRISMA diagram of the review

**Figure 2.** Risk of bias assessments showing the percentage of included studies with high, unclear, or low risk of bias in the population of A. healthy individuals; B. stroke; C. depression; and D. other disorders.



The copyright holder for this prepriation of this prepries and  $2024.1$  is a series November 7, 2024. The copyright repressive preprint this series or drive is a depicted to the copyright repressive in the copyright of  $20$ 

Table 1. Data extraction.













F: females, M: males, L: left, R: right, M1: primary motor cortex, DLPFC: dorsal lateral prefrontal cortex, FDI: first dorsal interosseous, ADM: abductor digiti minimi, RMT: resting motor threshold, AMT: active motor thres F: lemails, M: males, L: left, R: right, M1: primary motor cortex, DLPC: dorsal lateral prefrontal cortex, FDI: first dorsal interosseous, ADM: abductor digit: minmi, RMI: resting motor threshold, AMI: active motor thresho transformed MEP, SICI: short-interval intracortical inhibition, ICF: intracortical facilitation, FMA: Fugl Meyer Assessment, FMA-UL: Fugl Meyer Assessment-Upper Limb, FMA-LL: Fugl Meyer Assessment-Lower Limb, FMA-T: Fugl Meyer Assessment-Total, BBT: Box and Block Test, MoCA: Montreal Cognitive Assessment, LOTCA: Loewenstein Occupational Therapy Cognitive Assessment, RBMT: Rivermead Behavioral Memory Test, fMRI BOLD activation: functional magnetic resonance imaging blood oxygen level-dependent activation, WAB-AQ: Western Aphasia Battery-Aphasia Quotient, HAMD and HDRS: Hamilton Depression Rating Scale, NS: non-significant, N/A: not available

\*\* not all participants provided saliva sample for genotyping



# Reason 1: conference abstracts (N=16) Reason 2: reviews/commentaries (N=18) Reason 3: rTMS or TBS not used (N=32) Reason 4: article not in English (N=2) Reason 5: protocol registrations (N=6) Reason 6: animal studies (N=5)

Reason: all participants had the



Random sequence generation **Allocation concealment** Blinding of participants and researchers Blinding of outcome assessment Incomplete outcome data Selective reporting Other bias

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) . **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. nedRxiv preprint doi: [https://doi.org/10.1101/2024.11.06.24316617;](https://doi.org/10.1101/2024.11.06.24316617) this version posted November 7, 2024. The copyright holder for this preprin

> Random sequence generation **Allocation concealment** Blinding of participants and researchers Blinding of outcome assessment Incomplete outcome data Selective reporting Other bias

# A. Healthy



**C. Depression** 



 $\blacksquare$  low risk of bias





 $80\%$ 100%





100% 0%  $\blacksquare$  unclear risk of bias **■ high risk of bias**